Neurizon Therapeutics Completes Fastest HEALEY ALS Trial Enrolment, Boosts Funding
Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.
- Completed enrolment of 250 participants in HEALEY ALS Trial in under five months
- Net loss narrowed to $10.7 million from $16.6 million in prior year
- Secured five-year GMP supply agreement with Elanco Animal Health
- Raised $20.8 million via equity and convertible notes, plus non-dilutive R&D financing
- Topline Phase 2/3 trial results expected late Q2 2027
Record Fast Enrolment Accelerates Clinical Milestone
Neurizon Therapeutics Limited (ASX:NUZ) has marked a significant operational achievement by completing enrolment of 250 participants in its Phase 2/3 HEALEY ALS Platform Trial for NUZ-001, its lead investigational drug for Amyotrophic Lateral Sclerosis (ALS). This milestone was reached in under five months from first dosing, setting a new speed record for the trial platform and advancing the timeline for topline efficacy and safety results to late Q2 2027. The trial expansion from 160 to 250 participants was executed without increasing Neurizon's funding requirements, thanks in part to philanthropic support, underscoring disciplined cost management and robust recruitment momentum. This rapid enrolment materially de-risks the clinical program and strengthens the dataset for regulatory and commercial evaluation. 250 participants enrolled in record time
Improved Financial Position Amid Clinical Investment
Financially, Neurizon reported a net loss after tax of $10.7 million for the year ended 30 June 2026, a 35% improvement compared to a $16.6 million loss the previous year. This narrowing loss was driven by a substantial 844% increase in other income, primarily attributable to a $16.4 million Australian R&D tax incentive rebate related to eligible research expenditures. The company’s balance sheet strengthened considerably, with net assets rising to $12.7 million from $2.8 million a year earlier, supported by approximately $20.8 million raised through equity placements and convertible note issuances. Additionally, Neurizon secured a $17.5 million non-dilutive R&D financing facility to accelerate access to future tax incentive refunds, further enhancing capital flexibility while minimising shareholder dilution. These funding initiatives provide a solid runway through the upcoming clinical readouts. Raised $20.8 million via equity and convertible notes
Manufacturing and Intellectual Property Foundations Strengthened
On the operational front, Neurizon solidified its manufacturing and supply chain capabilities by entering a long-term, five-year GMP supply agreement with Elanco Animal Health, securing access to monepantel, the active pharmaceutical ingredient in NUZ-001. This deal mitigates supply risk and supports both ongoing clinical development and potential commercialisation. Complementing this, the company expanded its intellectual property portfolio with an Australian patent covering NUZ-001’s use in multiple neurodegenerative diseases through 2041 and secured trademark protections across key global markets, including the US and Europe. These moves bolster Neurizon’s scientific and regulatory positioning ahead of pivotal trial results. Five-year GMP supply agreement with Elanco
Scientific Progress and Regulatory Milestones
Neurizon’s lead candidate NUZ-001 targets disrupted cellular protein homeostasis via activation of autophagy and the ubiquitin-proteasome system, addressing the accumulation of misfolded proteins implicated in ALS and other neurodegenerative diseases. Preclinical data presented during the year demonstrated multi-pathway clearance activity and neuroprotective effects, including preservation of key neuronal proteins and restoration of cellular balance. Regulatory progress was highlighted by the FDA lifting a clinical hold in October 2025 after the company submitted bridging pharmacokinetic data, enabling the commencement of the HEALEY ALS Platform Trial. The trial is a global, adaptive, registrational study designed to efficiently evaluate promising ALS therapies under a shared protocol across 78 US clinical sites. This regulatory clearance and trial initiation marked Neurizon’s transition into late-stage clinical development. FDA lifted clinical hold on NUZ-001
Leadership and Governance Adapt to Growth Phase
The company’s governance adapted to its evolving clinical and operational complexity during FY2026. Interim Executive Chairman Sergio Duchini, with extensive biotech and finance experience, took the helm following the resignation of former CEO Dr Michael Thurn. The Board was further strengthened by the appointment of Dr Ross Murdoch, a seasoned pharmaceutical executive with expertise in neurology and global commercial strategy. Neurizon is actively searching for a permanent CEO, with an appointment expected in Q3 CY2026, signalling readiness for the next growth phase. The company continues to engage with the ALS community and industry stakeholders, reinforcing its patient-driven ethos. Interim Executive Chairman Sergio Duchini appointed
Bottom Line?
Neurizon’s swift trial enrolment and strengthened financial footing set a solid stage for its pivotal ALS study, but the real test lies in the late Q2 2027 topline readout.
Questions in the middle?
- Will the upcoming HEALEY ALS Platform Trial results validate NUZ-001’s disease-modifying potential in ALS?
- How will Neurizon leverage its manufacturing and IP assets to attract strategic partners ahead of commercialisation?
- What impact will the appointment of a permanent CEO have on execution and investor confidence in FY2027?
